| VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study M Scartozzi, L Faloppi, G Svegliati Baroni, C Loretelli, F Piscaglia, ... International journal of cancer 135 (5), 1247-1256, 2014 | 150 | 2014 |
| The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study M Santoni, A Rizzo, V Mollica, MR Matrana, M Rosellini, L Faloppi, ... Critical Reviews in Oncology/Hematology 170, 103596, 2022 | 146 | 2022 |
| Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients M Scartozzi, R Giampieri, E Maccaroni, M Del Prete, L Faloppi, ... British journal of cancer 106 (5), 799-804, 2012 | 125 | 2012 |
| The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management L Faloppi, M Scartozzi, M Bianconi, G Svegliati Baroni, P Toniutto, ... BMC cancer 14, 1-8, 2014 | 109 | 2014 |
| Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib AC Gardini, E Scarpi, L Faloppi, M Scartozzi, N Silvestris, D Santini, ... Oncotarget 7 (41), 67142, 2016 | 104 | 2016 |
| Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale AC Gardini, L Faloppi, S De Matteis, FG Foschi, N Silvestris, F Tovoli, ... European Journal of Cancer 86, 106-114, 2017 | 100 | 2017 |
| VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib M Scartozzi, M Bianconi, L Faloppi, C Loretelli, A Bittoni, M Del Prete, ... British journal of cancer 108 (5), 1126-1132, 2013 | 96 | 2013 |
| Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy R Giampieri, E Maccaroni, A Mandolesi, M Del Prete, K Andrikou, ... Gastric Cancer 20, 156-163, 2017 | 93 | 2017 |
| Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients M Scartozzi, I Bearzi, A Mandolesi, R Giampieri, L Faloppi, E Galizia, ... British journal of cancer 104 (11), 1786-1790, 2011 | 88 | 2011 |
| Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study A Rizzo, M Santoni, V Mollica, F Logullo, M Rosellini, A Marchetti, ... Expert Opinion on Drug Metabolism & Toxicology 17 (12), 1455-1466, 2021 | 83 | 2021 |
| Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib A Casadei Gardini, G Marisi, E Scarpi, M Scartozzi, L Faloppi, N Silvestris, ... Expert opinion on pharmacotherapy 16 (18), 2719-2725, 2015 | 75 | 2015 |
| The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment M D’Anzeo, L Faloppi, M Scartozzi, R Giampieri, M Bianconi, M Del Prete, ... Molecules 19 (5), 6393-6406, 2014 | 73 | 2014 |
| Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-taylored therapeutic options L Faloppi, M Scartozzi, E Maccaroni, MDP Paolo, R Berardi, M Del Prete, ... Cancer treatment reviews 37 (3), 169-177, 2011 | 73 | 2011 |
| Lactate dehydrogenase in hepatocellular carcinoma: something old, something new L Faloppi, M Bianconi, R Memeo, A Casadei Gardini, R Giampieri, ... BioMed research international 2016 (1), 7196280, 2016 | 70 | 2016 |
| Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? A Gnoni, D Santini, M Scartozzi, A Russo, A Licchetta, V Palmieri, L Lupo, ... Expert opinion on therapeutic targets 19 (12), 1623-1635, 2015 | 70 | 2015 |
| The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management M Scartozzi, L Faloppi, M Bianconi, R Giampieri, E Maccaroni, A Bittoni, ... PloS one 7 (3), e32653, 2012 | 67 | 2012 |
| Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular … M Scartozzi, GS Baroni, L Faloppi, MDP Paolo, C Pierantoni, R Candelari, ... Journal of Experimental & Clinical Cancer Research 29, 1-8, 2010 | 62 | 2010 |
| Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management M Del Prete, R Giampieri, F Loupakis, T Prochilo, L Salvatore, L Faloppi, ... Oncotarget 6 (32), 33982, 2015 | 59 | 2015 |
| The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib L Faloppi, M Bianconi, R Giampieri, A Sobrero, R Labianca, D Ferrari, ... Oncotarget 6 (33), 35087, 2015 | 52 | 2015 |
| First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase … A Ravaud, S Oudard, G Gravis-Mescam, E Sevin, S Zanetta, C Theodore, ... Journal of Clinical Oncology 27 (15_suppl), 5146-5146, 2009 | 51 | 2009 |
